GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oragenics Inc (LTS:0A64) » Definitions » Cash Receipts from Fees and Commissions

Oragenics (LTS:0A64) Cash Receipts from Fees and Commissions


View and export this data going back to 2021. Start your Free Trial

What is Oragenics Cash Receipts from Fees and Commissions?

Cash Receipts from Fees and Commissions only applicable to companies reporting Cash Flow from Operations in direct method.


Oragenics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oragenics Inc (LTS:0A64) » Definitions » Cash Receipts from Fees and Commissions
Traded in Other Exchanges
Address
1990 Main Street, Suite 750, Sarasota, FL, USA, 34236
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.